Ascelia Pharma AB (CHIX:ACEs)

Q4 2025 Ascelia Pharma AB Earnings Call Transcript

Feb 6, 2026 / 12:00 PM GMT

Release Date Price: kr45.05

Transcript

Key Points

Positve

Ascelia Pharma AB (FRA:7ZA) is in the FDA review process for its first-in-class diagnostic drug, Origlans, with an expected decision by July 3, 2026.
The company has a strong pipeline with two drugs, including Origlans and Onorol, targeting rare oncology settings.
Origlans addresses a well-defined unmet medical need in liver imaging for cancer patients with severe renal impairment, representing an $800 million global market opportunity.
The company has commercial-scale manufacturing in place and has completed an extensive clinical program with positive results, particularly in the phase 3 trial.
Ascelia Pharma AB (FRA:7ZA) has filed a new patent application for Origlans, enhancing its intellectual property protection and potentially extending its market exclusivity.

Negative

The company is still in the process of finding a commercialization partner for Origlans, which could impact the timeline for market launch.
There are concerns about the potential environmental impact of gadolinium, which Origlans aims to replace, but this issue could affect market perception.
Ascelia Pharma AB (FRA:7ZA) reported an operating loss of approximately 16 million in Q4 2025, indicating ongoing financial challenges.
The company has financing only until Q4 2026, which may necessitate additional capital raising efforts if a partnership is not secured soon.
The departure of Deputy CEO Julie, who has been with the company for six years, could lead to transitional challenges in leadership.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ACELP.ST - Ascelia Pharma AB
Q4 2025 Ascelia Pharma AB Earnings Call
Feb 06, 2026 / 12:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Welcome to today's presentation where we have the pleasure to present Acadia Farmer.

Today's event, of course, covering your Q4 full year report sent out yesterday, but as the situation is with you, it's maybe not the financials that's the most interesting. We have a lot of questions, so I think we'll get very well around the case. But, of course, that's the occasion why we are doing this, but, let's take a broader look also at your company. To help us through it, we're joined by CEO Manus Corvisen, as always, there's a box down below, ask questions during the presentation, we got a lot in advance, and we have, we need unfortunately, a little bit after half to break off the event. So, let's see what we can catch, but, for now I

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.